{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:35:41Z","timestamp":1790908541912,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.leukres.2014.10.005","type":"journal-article","created":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T12:16:43Z","timestamp":1414844203000},"page":"58-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors"],"prefix":"10.1016","volume":"39","author":[{"given":"J.H.","family":"Lipton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bryden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.K.","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.J.","family":"McGarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lustgarten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mealing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2014.10.005_bib0005","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.10.005_bib0010","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib","volume":"22","author":"Hochhaus","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.10.005_bib0015","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2014.10.005_bib0020","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.10.005_bib0025","unstructured":"Pfizer Bosulif Prescribing Information, Sep 2013. 2013."},{"key":"10.1016\/j.leukres.2014.10.005_bib0030","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O\u2019Hare","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.10.005_bib0035","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2014.10.005_bib0040","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2014.10.005_bib0045","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1182\/blood.V122.21.652.652","article-title":"Impact of baseline (BL) mutations, including low-level and compound mutations, on ponatinib response and end of treatment (EOT) mutation analysis in patients (Pts) with chronic phase chronic myeloid leukemia (CP-CML)","volume":"122","author":"Shah","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.10.005_bib0050","unstructured":"ARIAD Pharmaceuticals Inc. Press release. Cambridge, MA, October 9, 2013."},{"key":"10.1016\/j.leukres.2014.10.005_bib0055","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1182\/blood-2009-05-221531","article-title":"The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up","volume":"114","author":"Garg","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.10.005_bib0060","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3324\/haematol.2012.080234","article-title":"The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis","volume":"98","author":"Nicolini","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2014.10.005_bib0065","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1182\/blood-2010-06-291922","article-title":"Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy","volume":"116","author":"Ibrahim","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.10.005_bib0070","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/blood-2013-07-513937","article-title":"Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors","volume":"123","author":"Kantarjian","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.10.005_bib0075","series-title":"Clinical practice guidelines in oncology: chronic myelogenous leukemia V2.1014","author":"National Comprehensive Cancer Network","year":"2014"},{"key":"10.1016\/j.leukres.2014.10.005_bib0080","first-page":"163","volume":"120","author":"Cortes","year":"2012","journal-title":"ASH Annu Meeting Abstr"},{"key":"10.1016\/j.leukres.2014.10.005_bib0085","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2014.10.005_bib0090","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2014.10.005_bib0095","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.10.005_bib0100","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2006-07-035493","article-title":"Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure","volume":"109","author":"Quintas-Cardama","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.10.005_bib0105","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2010.110","article-title":"Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy","volume":"24","author":"Giles","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.10.005_bib0110","first-page":"257","article-title":"Expanding nilotinib access in clinical trials (ENACT) study in adult patients (Pts.) with imatinib-resistant or -intolerant chronic myeloid leukaemia (CML): Subgroup analysis of patients who failed prior dasatinib therapy","volume":"94","author":"Nicolini","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2014.10.005_bib0115","first-page":"3764","article-title":"Outcomes of chronic myeloid leukemia (CML) Patients who stopped second generation tyrosine kinase inhibitors (2GTKIs) as second line treatment. Results of the CML Spanish National Registry (RELMC)","volume":"120","author":"Garcia-Gutierrez","year":"2012","journal-title":"ASH Annual Meeting Abstr"},{"key":"10.1016\/j.leukres.2014.10.005_bib0120","article-title":"Outcome of patients with chronic phase CML treated with dasatinib or nilotinib after failure of second prior TKIs","author":"Russo Rossi","year":"2011","journal-title":"EHA Meeting Abstr"},{"key":"10.1016\/j.leukres.2014.10.005_bib0125","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.clml.2011.06.009","article-title":"The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?","volume":"11","author":"Cortes","year":"2011","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"10.1016\/j.leukres.2014.10.005_bib0130","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1182\/blood-2009-04-219410","article-title":"Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation","volume":"114","author":"Nicolini","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.10.005_bib0135","series-title":"NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia, v.2.2014","author":"NCCN","year":"2013"},{"key":"10.1016\/j.leukres.2014.10.005_bib0140","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/cncr.23238","article-title":"Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?","volume":"112","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2014.10.005_bib0145","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1080\/10428190500473055","article-title":"Development of a predictive population survival model according to the cytogenetic response rate for patients with chronic myeloid leukemia in the chronic phase","volume":"47","author":"Schrover","year":"2006","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.leukres.2014.10.005_bib0150","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jval.2013.07.004","article-title":"Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence","volume":"16","author":"Oriana","year":"2013","journal-title":"Value Health: J Int Soc Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.leukres.2014.10.005_bib0155","article-title":"The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports","volume":"3","author":"Taylor","year":"2009","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.leukres.2014.10.005_bib0160","series-title":"SYNBRIO prescribing information","author":"Teva Pharmaceuticals USA Inc.","year":"2012"},{"key":"10.1016\/j.leukres.2014.10.005_bib0165","first-page":"6596","article-title":"Omacetaxine mepesuccinate in chronic-phase chronic myeloid leukemia (CML) in patients resistant, intolerant, or both to two or more tyrosine-kinase inhibitors (TKIs)","volume":"30","author":"Akard","year":"2012","journal-title":"ASCO Meeting Abstr"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614003270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614003270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:58:52Z","timestamp":1758934732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212614003270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0145212614003270"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2014.10.005","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2014.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}